Wall Street brokerages predict that PerkinElmer, Inc. (NYSE:PKI) will post earnings of $0.94 per share for the current fiscal quarter, according to Zacks Investment Research. Six analysts have provided estimates for PerkinElmer’s earnings, with the highest EPS estimate coming in at $0.95 and the lowest estimate coming in at $0.92. PerkinElmer posted earnings of $0.83 per share during the same quarter last year, which would suggest a positive year over year growth rate of 13.3%. The firm is scheduled to issue its next earnings results on Thursday, February 1st.

On average, analysts expect that PerkinElmer will report full-year earnings of $2.88 per share for the current financial year, with EPS estimates ranging from $2.87 to $2.90. For the next financial year, analysts expect that the firm will post earnings of $3.16 per share, with EPS estimates ranging from $3.13 to $3.20. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that cover PerkinElmer.

A number of research firms have weighed in on PKI. Morgan Stanley lifted their price objective on shares of PerkinElmer from $77.00 to $78.00 and gave the company an “overweight” rating in a report on Friday, November 3rd. Citigroup Inc. reaffirmed a “buy” rating and issued a $80.00 price objective (up previously from $74.00) on shares of PerkinElmer in a report on Tuesday, September 26th. Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and issued a $67.00 price objective on shares of PerkinElmer in a report on Tuesday, September 26th. Zacks Investment Research raised shares of PerkinElmer from a “hold” rating to a “buy” rating and set a $74.00 price objective for the company in a report on Tuesday, August 1st. Finally, Robert W. Baird lifted their price objective on shares of PerkinElmer from $75.00 to $78.00 and gave the company an “outperform” rating in a report on Friday, November 3rd. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $68.64.

In other news, Director Nicholas A. Lopardo sold 24,050 shares of the company’s stock in a transaction that occurred on Tuesday, November 7th. The shares were sold at an average price of $70.72, for a total value of $1,700,816.00. The sale was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 2.20% of the company’s stock.

Hedge funds have recently modified their holdings of the company. FMR LLC lifted its holdings in PerkinElmer by 46.8% during the 1st quarter. FMR LLC now owns 272,519 shares of the medical research company’s stock worth $15,822,000 after buying an additional 86,838 shares in the last quarter. Teachers Advisors LLC lifted its holdings in PerkinElmer by 6.1% during the 1st quarter. Teachers Advisors LLC now owns 346,680 shares of the medical research company’s stock worth $20,128,000 after buying an additional 19,854 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in PerkinElmer by 15.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 891,832 shares of the medical research company’s stock worth $51,778,000 after buying an additional 118,995 shares in the last quarter. Morgan Stanley lifted its holdings in PerkinElmer by 10.5% during the 1st quarter. Morgan Stanley now owns 272,720 shares of the medical research company’s stock worth $15,834,000 after buying an additional 25,976 shares in the last quarter. Finally, Credit Suisse AG increased its position in shares of PerkinElmer by 6.5% in the 1st quarter. Credit Suisse AG now owns 108,618 shares of the medical research company’s stock valued at $6,306,000 after purchasing an additional 6,665 shares during the last quarter. Hedge funds and other institutional investors own 91.38% of the company’s stock.

WARNING: This piece was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another site, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/brokerages-expect-perkinelmer-inc-pki-will-post-earnings-of-0-94-per-share/1698739.html.

PerkinElmer (NYSE PKI) traded down $0.13 during midday trading on Friday, reaching $71.33. 1,027,600 shares of the company were exchanged, compared to its average volume of 575,442. PerkinElmer has a 52 week low of $49.72 and a 52 week high of $73.05. The company has a quick ratio of 2.09, a current ratio of 2.59 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $7,862.35, a P/E ratio of 25.66, a PEG ratio of 2.01 and a beta of 0.77.

The company also recently announced a quarterly dividend, which will be paid on Friday, February 9th. Shareholders of record on Friday, January 19th will be issued a $0.07 dividend. The ex-dividend date of this dividend is Thursday, January 18th. This represents a $0.28 annualized dividend and a yield of 0.39%. PerkinElmer’s payout ratio is 7.78%.

About PerkinElmer

PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.

Get a free copy of the Zacks research report on PerkinElmer (PKI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.